Top 50 Cell Line Development in Europe

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

The startup operates a cell therapy research and manufacturing platform that enhances process control and scalability in autologous cell and gene therapy bioprocessing. By enabling parallel execution of cell culture conditions, the platform reduces manufacturing costs while improving efficiency in process development.

The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

CellRev specializes in process intensification for cell manufacturing through advanced bioprocessing techniques that enhance yield and efficiency. The company reduces high production costs and lengthy timelines in biomanufacturing, facilitating faster and more cost-effective development of cell-based therapies.

Core Biogenesis utilizes proprietary plant-based bioproduction technologies to manufacture animal-free, endotoxin-free recombinant growth factors and cytokines for cell culture applications. This approach enhances the consistency and reproducibility of cell cultures, addressing the critical issue of endotoxin contamination in biomanufacturing processes.

The startup develops bacterial protein polymers that deliver bioactive cues essential for cell growth and division, specifically for cultivated meat and cell therapy manufacturing. This technology provides a cost-effective and multifunctional material that meets the needs of biomedical research and therapy markets at an industrial scale.

Virocell Biologics is a contract development and manufacturing organization (CDMO) that specializes in producing viral vectors for gene therapy and vaccine applications, ensuring compliance with biopharmaceutical quality standards. The company offers scalable manufacturing solutions that enhance the efficiency and reliability of therapeutic development processes.

Cellcolabs specializes in the industrial-scale, GMP production of high-quality mesenchymal stromal cells (MSCs) for research and clinical applications. By providing these cells, the company aims to enhance the availability and affordability of MSCs, facilitating advancements in treatments for severe and incurable diseases.

Roslin Technologies develops pluripotent animal stem cells for the cultivated meat industry, providing scalable cell lines that can differentiate into muscle and fat tissues. This technology addresses the growing global demand for sustainable protein by enabling the production of real meat without raising animals, thereby reducing environmental impact and improving animal welfare.

Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.

Qkine develops and manufactures high-quality, animal-free growth factor proteins specifically for stem cell, organoid, and cellular agriculture applications, ensuring consistent bioactivity through rigorous quality control. Their products address the need for reproducible and reliable biological materials in research and industry, enhancing scientific outcomes across various fields.

Limula provides a modular, automated platform that integrates a bioreactor and centrifuge for the on-demand, at-scale manufacturing of cell therapies. This technology addresses the high costs and complexity of producing personalized cell therapies, enabling efficient processing of various cell types in a single device.

Kytopen develops a non-viral gene delivery platform, Flowfect®, that utilizes continuous fluid flow and electric fields to efficiently deliver mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes. This technology addresses the challenges of cell therapy manufacturing by enabling scalable and customizable transfection processes from discovery to large-scale production.

Ensocell utilizes single-cell genomics, AI-driven computational tools, and advanced cell models to identify intervention points for autoimmune, inflammatory, and fibrotic diseases. The company focuses on discovering novel therapeutics to improve treatment outcomes in these challenging health conditions.

Newcells Biotech specializes in developing induced pluripotent stem cell-derived in vitro models for drug discovery, focusing on human tissue simulations such as retinal, kidney, and lung models. Their services provide critical data on drug efficacy and safety, enhancing the predictive accuracy of pre-clinical studies and facilitating clinical translation.

Astraveus is developing the Lakhesys - The Benchtop Cell Factory™, a microfluidics-powered platform that integrates hardware, software, and consumables for cell and gene therapy manufacturing. This solution enhances development throughput by up to 100 times while reducing resource consumption by 10 to 20 times, making cell therapies more accessible to patients.

The startup has developed a fluid-shaping technology that replaces traditional microtiter plates with a microscale system for single-cell cloning, allowing researchers to expose cells to relevant experimental conditions. This technology enables multiple users to conduct simultaneous experiments efficiently, addressing the limitations of current cloning methods.

The startup develops a machine platform that integrates silicon chip technology with microfluidic processing for the large-scale manufacturing of personalized cell therapies. This technology enables real-time control and manipulation of cellular processes, providing cost-effective and safe treatments tailored for individual cancer patients.

PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.

PL BioScience provides human Platelet Lysate-based 2D and 3D cell culture solutions that serve as a xeno-free alternative to Fetal Bovine Serum, addressing the need for safer and more effective growth environments in research and clinical applications. Their ELAREM™ platform offers various grades of human Platelet Lysate, ensuring compliance with safety standards for diverse applications in regenerative medicine and cellular therapeutics.

Multus develops animal-free growth media formulations for cellular agriculture, utilizing data science and high-throughput automation to create scalable, cost-effective solutions. Their products replace traditional fetal bovine serum with serum-free alternatives, enabling cultivated meat companies to reduce input costs and enhance bioprocess performance.

Unicorn Biotechnologies develops bio-reactors that standardize, digitize, and automate cell culture workflows, enabling efficient scaling from pilot to commercial manufacturing. Their technology addresses the challenges of batch failures and high costs in cell-based production, allowing researchers to focus on experimental design and analysis.

Scarlet Therapeutics develops a proprietary platform that generates therapeutic red blood cells (tRBCs) containing high levels of therapeutic proteins, enabling targeted treatment for diseases such as hyperammonemia, hyperoxaluria, cancer, and autoimmune disorders. By utilizing cell lines for production instead of donated stem cells, the company addresses manufacturing challenges and enhances the efficacy of red blood cell-based therapies.

Extracellular is a contract development and manufacturing organization (CDMO) that specializes in biomanufacturing processes for cultivated meat and seafood, utilizing non-human cell culture technologies to produce biomass efficiently. The company addresses the challenge of scaling production in sustainable biotechnology by providing tailored cell culture media and large-scale bioreactor capabilities to accelerate time to market for its clients.

Cellular Origins develops the Constellation robotic automation platform for the scalable manufacturing of cell and gene therapies, integrating production equipment to enhance efficiency. This technology reduces labor by 16 times, cuts costs by 51%, and enables closed, data-rich production processes to meet the growing demand for cell therapies.

TreeFrog Therapeutics develops proprietary C-Stem™ technology to produce scalable, high-quality cell therapies, including a lead program targeting Parkinson’s disease. The company addresses the need for effective and safe regenerative medicine by enabling the production of billions of cells in a single batch, facilitating clinical trials and patient access.

The startup provides contract development and manufacturing services for lentiviral vectors, utilizing customized design and cloning tools tailored to client specifications. This enables researchers to conduct targeted tests on rare diseases and hematological cancers, facilitating advancements in gene therapy and personalized medicine.

Mogrify develops in vivo reprogramming therapies that utilize a proprietary platform to identify key transcriptomic and epigenetic factors necessary for direct cellular conversion. This technology aims to restore lost cell types in patients with degenerative diseases, particularly in otology, ophthalmology, and diabetes, addressing significant unmet clinical needs.

Doppl operates a crowd-sourced biobank that collects biological samples from citizen donors to facilitate personalized medicine and drug development. The company specializes in engineering organoid models for preclinical drug testing, addressing the need for relevant and scalable disease models in medical research.

The company develops therapeutics that target and modulate fibroblasts to address diseases such as cancer and fibrosis, which are driven by pathologically activated fibroblasts that disrupt normal tissue structure. By selectively modulating these cells, the company aims to create transformative treatments that improve patient outcomes in affected populations.

Arsenale BioYards is a bio-manufacturing platform that combines hardware and software to facilitate the design and cultivation of engineered cells for product creation. This technology enables a shift from resource extraction to sustainable cellular farming, addressing the need for a more efficient and environmentally friendly bioeconomy.

The startup develops label-free cellular-based screening methods to identify and advance drug candidates for severe autoimmune and inflammatory disorders. This approach enables healthcare professionals to provide targeted therapies for patients with significant unmet medical needs.

Singleron Biotechnologies provides end-to-end single cell multi-omics solutions, utilizing proprietary technologies for tissue preservation, dissociation, and automated bioinformatics analysis. Their offerings enable researchers to efficiently generate high-quality single cell sequencing data, addressing the challenges of time-consuming sample processing and complex data interpretation in precision medicine.

SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.

The startup develops AI-driven live-cell imaging technology to predict and optimize stem cell differentiation, enabling the scalable manufacture of any cell or tissue in the body. This approach addresses the need for effective stem cell-based therapies for chronic diseases, facilitating data-driven drug development and improving patient outcomes.

CryoLogyx develops cryopreserved, assay-ready cells that are directly adhered to microplates, enabling experiments to commence just 24 hours post-thaw. This technology enhances the precision and efficiency of cell-based research, significantly reducing the time and resources required for routine cell culture.

The startup specializes in droplet microfluidics technology to facilitate the detection and selection of living biological cells, including therapeutic antibody producers and rare immune cells. This approach enables life science researchers to analyze biological samples at the single-cell level with increased speed and precision, addressing the limitations of conventional manipulation techniques.

This startup develops advanced therapy medicinal products (ATMPs) using personalized approaches. They focus on discovering novel therapies with regulatory-compliant and quality-managed systems to improve patient treatment outcomes.

Mo:re is developing a robotic and software platform that automates 3D cell culture processes for medical research, enhancing traceability and reproducibility in experiments. This technology enables researchers to conduct drug development and screening more efficiently, reducing time and costs associated with traditional methods.

The startup has developed a scalable purification platform that removes unwanted cells from stem cell products, addressing the critical issue of cellular impurities in cell therapy manufacturing. By utilizing deep analytics and a flexible workflow, the platform ensures the production of safer, higher-quality stem cell therapies in any laboratory setting.

The startup has developed a cell-based biomanufacturing platform that isolates and cultivates plant vascular stem cells to produce bioactive molecules for commercial use. This technology enables the efficient production of sustainable food alternatives, addressing the growing demand for environmentally friendly solutions in the cosmetic, pharmaceutical, food, and agricultural sectors.

RootPath Genomics develops a personalized T cell therapy platform utilizing molecular programming-based DNA fragment assembly technology to provide researchers with scalable access to long synthetic genes and their functional readouts. This approach addresses the need for efficient gene function interrogation in precision medicine, enabling faster and more accurate therapeutic development.

The startup has developed a recombinant protein production technology that removes the origin of replication from bacterial chromosomes, allowing cells to remain metabolically active without dividing. This approach enables users to decouple protein production from cellular growth, enhancing yield and efficiency in biomanufacturing processes.

This biotechnology company programs cell metabolism to optimize biomanufacturing processes. They use metabolic modeling and minimal data to design custom cell culture media, enabling efficient production of advanced therapies.

The startup develops regenerative drugs using differentiated pluripotent stem cells to treat liver diseases, specifically targeting acute and chronic severe liver failure. By formulating frozen allogeneic liver cells, the company provides a therapeutic alternative to organ transplantation, enhancing treatment options for patients.

Oncolines provides precision medicine services for oncology and immunotherapy through bioinformatics analysis, gene mutation profiling, and tissue sensitivity testing. The company enables the identification of patient selection markers and the development of targeted therapies, facilitating faster access to effective treatments for specific patient populations.